Regulation Update · National · Published May 5, 2026

On Sunday night, John Oliver dedicated a long-form segment of Last Week Tonight to what he called "the fake gas station pill industrial complex" — and tens of millions of viewers heard the term 7-hydroxymitragynine for the first time. The conversation about how to regulate 7-OH is no longer happening in obscure FDA dockets and state legislative subcommittees. It's playing out in living rooms across America. That's a good thing. But the framing matters — because the next twelve months of policy decisions will determine whether this molecule's potential is harnessed or squandered.

What Oliver Actually Said

Oliver's segment was sharp, funny, and — to his credit — more careful than most cable-news takes. He spotlighted real harms: people running through tens of thousands of dollars on isolated 7-OH products, manufacturers ordering pre-printed pill bottles off Alibaba, premature ejaculation pills sold at ten times their labeled dose. The criticism wasn't unfair. The unregulated end of the gas-station-supplement market is genuinely dangerous, and the segment named names where they deserved to be named.

What stood out, though, was Oliver's closing argument. After 25 minutes of well-deserved roasting, he didn't call for a federal ban. He said this:

"Something clearly has to be done with this industry. The key thing is to do it very carefully… If states are going to ban some of these drugs, that should only happen alongside a plan to help people who cannot suddenly stop using them."

That is not a prohibitionist position. It is a harm-reduction position. And it lines up almost exactly with what evidence-based researchers, libertarian-leaning policy institutes, and patient-advocacy groups have been saying for two years.

The Bigger Story Oliver Didn't Tell

Between September 2023 and September 2024, the United States recorded a 24% decline in drug overdose deaths — the sharpest single-year drop in decades. The CDC's most recent provisional figures (12 months ending November 2025) project roughly 70,231 deaths, a further 15.9% decline year-over-year. After thirty years of escalation, the curve finally bent.

Researchers are still working out why. Naloxone access, fentanyl test strips, methadone telehealth, and the natural saturation of an overdose population all play roles. But a question worth asking, and one a small but growing chorus of harm-reduction researchers are now asking out loud, is whether consumer-driven adoption of plant-derived alkaloids — including kratom and isolated 7-OH — has quietly contributed to the decline.

A preliminary 2025 community survey of 7-OH users (N=122) found that 84% reported reduced reliance on prescription pain medication after 30 days of consistent use, and 68% reported improved daily functionality without sedation. R Street Institute's 2025 review noted that roughly two-thirds of kratom users explicitly use the plant as a substitute for opioids — heroin, oxycodone, fentanyl. These are not recreational users looking for a buzz. They are people who, for whatever reason, stopped getting their pain treated by the medical system and went looking for something that worked.

The hypothesis is not that 7-OH is a miracle cure. The hypothesis is that millions of Americans found a partial mu-opioid agonist with a different safety profile than fentanyl, used it instead of fentanyl, and survived. That hypothesis deserves to be tested — not legislated out of existence before the data is in.

The Science Gap Is Real — And It Cuts Both Ways

Oliver was right that the research base on isolated 7-OH is thin. He was right that we do not have good controlled-trial data on dependence liability, long-term safety, or interaction profiles. Anyone who tells you otherwise is selling something.

But the response to a thin evidence base is more research, not prohibition. The FDA's own 2025 assessment of 7-OH explicitly identified research gaps as a reason to study the molecule more carefully — not as license to schedule it. The DEA has been considering Schedule I designation for over two years and has not finalized it, in part because Schedule I status would freeze the very research that would answer the FDA's questions. That is the prohibition trap: once a substance is Schedule I, almost no one can legally study it, so the evidence base never improves, so the scheduling never gets revisited.

We know enough about 7-OH's pharmacology to say two things with confidence: it is a partial agonist at the mu-opioid receptor (which carries a different respiratory-depression profile than full agonists like fentanyl), and concentrated isolates behave very differently than the trace amounts (typically <0.1%) found in whole-leaf kratom. Those two facts alone are the entire argument for concentration-based regulation rather than blanket prohibition.

What Smart Regulation Actually Looks Like

The Kratom Consumer Protection Act framework — already enacted in some form by Arizona, Georgia, Utah, Nevada, and a growing list of states — is the model that works. It treats 7-OH like nicotine, alcohol, or pharmaceutical-grade caffeine: a substance that adults can choose to use, with industry guardrails that protect everyone else. A complete framework looks like this:

  • 21+ age verification at point of sale, online and in-store. Non-negotiable.
  • Mandatory ISO/IEC 17025 third-party lab testing on every batch, with the Certificate of Analysis published publicly. Not "we tested it once in 2022." Every batch.
  • Concentration caps with scientific basis — not arbitrary "2% of total alkaloids" rules pulled from one state's lobbying compromise. Caps should reflect dose-response curves, not political compromise.
  • Banned synthetic adulterants — no synthetic 7-OH, no fillers, no undisclosed analogues. The honest end of the industry already does this. The dishonest end is what Oliver was filming in gas stations.
  • Child-resistant, plain packaging. No cartoon characters. No "now in bubblegum flavor" marketed at 13-year-olds.
  • Honest labeling: full alkaloid breakdown, dose per serving, suggested limits, and a clear statement that this product is not for users with active opioid use disorder without medical supervision.
  • Funded research: a small federal excise tax (or industry-funded NIH consortium) directed at independent dependence-liability studies, harm-reduction outcome data, and safety pharmacology. The industry should welcome this.
  • Off-ramp services for users who develop dependence — exactly what Oliver called for. Telehealth access to buprenorphine, peer-support groups, and transparent dependence resources on every product label.

None of that requires Schedule I designation. None of it requires a federal ban. All of it can happen this year if state legislators and federal regulators choose evidence over panic.

The Stakes of Getting This Wrong

Prohibition does not eliminate demand. It reroutes it. If 7-OH is scheduled federally and the regulated market shuts down, the millions of Americans who have substituted it for opioids do not stop using opioids — they go back to opioids, and the opioids they go back to in 2026 are not Vicodin from a pharmacy. They are pressed pills laced with fentanyl analogues bought from someone they don't know. The 24% overdose decline could reverse. Quickly.

This is not a hypothetical. We watched it happen with prescription opioid restrictions in 2014–2017: every clinic that stopped writing prescriptions sent its patients into a heroin-then-fentanyl pipeline. Whatever else 7-OH is, it is currently functioning as a pressure valve. Closing the valve without a plan is policy malpractice.

What Now

If you take one thing from John Oliver's segment, take this: the conversation is finally happening at scale, and the framing is up for grabs. The reflexive prohibitionist response — "this is unregulated, ban it" — is what got us mass incarceration, the failed war on drugs, and the modern fentanyl crisis. We have decades of evidence about what that approach produces. It produces more death.

The harder, slower, more durable answer is the one Oliver gestured at in his closing minute and the one R Street, the American Kratom Association, and a growing roster of independent researchers have been arguing for: regulate the industry, fund the science, protect minors, support users who develop dependence, and let adults make informed choices about plant-based pain management while we figure out what this molecule actually is.

That is not a fringe position. It is the position of every credible policy review of 7-OH published in the last two years. The next twelve months will tell us whether anyone in power was listening.

What you can do

If you live in a state currently considering a 7-OH ban or KCPA legislation, contact your state representative. Identify yourself as a constituent. Ask for evidence-based regulation, not prohibition. Reference the FDA's own 2025 assessment, R Street's 2025 review, and the harm-reduction literature.

Check your state's status on our live Kratom Regulation Map, and read our deeper coverage in the Regulations blog archive.

Sources & Further Reading

This article is editorial commentary, not medical advice. 7-OH is not currently approved by the FDA for the treatment, prevention, or cure of any disease. Use only as labeled. 21+. If you are struggling with opioid use disorder, contact SAMHSA's National Helpline at 1-800-662-4357 (free, confidential, 24/7).